Innovative Research, Inclusive Trials, and New Funding Drives Hope for People with Parkinson’s Disease featuring PhotoPharmics
PhotoPharmics Secures $16 Million Investment Led by Kickstart to Fund Pivotal Clinical Trial for FDA Market Authorization
This investment is a pivotal moment in our journey to transform the treatment landscape for Parkinson’s disease.”— Kent Savage, CEO
AMERICAN FORK, UT, UNITED STATES, November 15, 2023 /EINPresswire.com/ — PhotoPharmics, an innovator in Parkinson’s disease research and treatment, today announced the successful first close of an $16 million investment round. The investment round, led by Kickstart Fund, a venture capital firm based in Salt Lake City, marks a significant milestone in PhotoPharmics’ mission to revolutionize Parkinson’s disease treatment.
